Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy

Pharmaceutical Care and Research

Volumn 11, Issue 4, 2011, Pages 266-268

  Zheng, HongFang ^a   Qiu, Hong ^a   Liu, XinYan ^a   Jiang, BeiHu ^a  

^a Shanghai Putuo District Central Hospital   (China)

Author keywords

Aldosterone escape; Benazepril; Diabetic nephropathy; Quantity of urine protein; Spironolactone

Indexed keywords

ALDOSTERONE; BENAZEPRIL; CREATININE; POTASSIUM; SPIRONOLACTONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; HUMAN; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL;

EID: 80052742533     PISSN: 16712838     EISSN: None     Source Type: Journal    
DOI: 10.5428/pcar20110408     Document Type: Article

References (7)

1. Molitch M E. Management of early diabetic nephropathy[J]. Am J Med, 1997, 102(4): 392-398. (Pubitemid 27249107)
2. Liu Gang, Wang HaiYan. Specificity therapy of idiopathic membranous nephropathy[J]. Chin J Nephrol, 2002, 18(6): 450-451. Chinese.
3. Lin ShanDu, Wang HaiYan. Diabetic nephropathy[M]//Wang HaiYan. Nephrology. 3rd ed. Beijing: People's Health Press, 2008: 414-434. Chinese.
4. Sonkodi S, Mogyorósi A. Treatment of diabetic nephropathy with angiotensin II blockers[J]. Nephrol Dial Transplant, 2003, 18(Suppl 5): v21-v23. (Pubitemid 36896443)
5. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease[J]. Am J Hypertens, 2005, 18(1): 44-49. (Pubitemid 40187348)
6. Han K H, Kang Y S, Han S Y, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats[J]. Kidney Int, 2006, 70(1): 111-120. (Pubitemid 44000127)
7. Epstein M, Williams G H, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes[J]. Clin J Am Soc Nephrol, 2006, 1(5): 940-951.